专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006090198A8 PLANT EXTRACTS AND METHODS AND USES THEREFORE 审中-公开
标题翻译：植物提取物及其用途及其用途
公开(公告)号：WO2006090198A8
公开(公告)日：2011-06-30
申请号：PCT/IB2005000474
申请日：2005-02-23
申请人： AVESTHA GENGRAINE TECH PVT LTD , PATELL VILLOO MORAWALA , VYAS DHRUVDEV
发明人： PATELL VILLOO MORAWALA , VYAS DHRUVDEV
IPC分类号： A61K36/61 , A01N65/00
CPC分类号： A61K36/185
摘要： The invention relates to compositions such as pharmaceutical compositions and comestibles comprising extracts of Terminalia arjuna and methods for preventing or treating diabetes, obesity, cardiovascular disease, cancer and related disease conditions in mammals, such as humans, and uses therefore.
摘要翻译：本发明涉及组合物，例如包含Terminalia arjuna的提取物的药物组合物和食物，以及用于预防或治疗哺乳动物（例如人）中的糖尿病，肥胖症，心血管疾病，癌症和相关疾病状况的方法。

2. 发明申请

WO2008004119A2 EUGENIA JAMBOLANA PLANT EXTRACTS FOR TREATING OSTEOPOROSIS AND THE EXTRACTION PROCESS THEREOF 审中-公开
标题翻译： EUGENIA JAMBOLANA植物提取物治疗骨质疏松症及其提取方法
公开(公告)号：WO2008004119A2
公开(公告)日：2008-01-10
申请号：PCT/IB2007002064
申请日：2007-07-09
申请人： AVESTHA GENGRAINE TECH PVT LTD , PATELL VILLOO MORAWALA
发明人： PATELL VILLOO MORAWALA
CPC分类号： A61K36/61 , A23L33/105 , A23V2002/00 , A23V2250/21 , A23V2200/306
摘要： The invention relates to compositions and methods for preventing, treating, or managing osteoporosis or conditions which are characterized by increased bone resorption, comprising administration of a prophylactically and therapeutically effective amount of Eugenia jambolana plant or extracts thereof to a mammal in need of such therapy. Preferably the mammal is human and the compositions comprise of single extract or a combination of extracts thereof. The present invention further relates to extracts which are isolated from different parts of Eugenia jambolana plant, the preparation of such extracts, the medicaments containing said extracts, and the use of these extracts and constituents for the preparation of a medicament. The present invention also relates to the process for preparing the extracts from various parts of Eugenia jambolana plant.
摘要翻译：本发明涉及用于预防，治疗或控制以骨再吸收增加为特征的骨质疏松症或病症的组合物和方法，其包括向需要这种治疗的哺乳动物施用预防和治疗有效量的番木瓜植物或其提取物。优选地，所述哺乳动物是人类，并且所述组合物包含单一提取物或其提取物的组合。本发明进一步涉及分离自番荔枝（Eugenia jambolana）植物不同部分的提取物，这些提取物的制备，含有所述提取物的药物，以及这些提取物和成分在制备药物中的用途。本发明还涉及从胡枝子番荔枝属植物的各个部分制备提取物的方法。

3. 发明申请

WO0130990A3 ISOLATED NUCLEIC ACID SEQUENCE CONFERRING SALT TOLERANCE IN RICE PLANT 审中-公开
标题翻译：分离核酸序列确定稻株中的耐盐性
公开(公告)号：WO0130990A3
公开(公告)日：2001-12-27
申请号：PCT/IN0000099
申请日：2000-10-11
申请人： AVESTHA GENGRAINE TECH PVT LTD , PATELL VILLO MORAWALA , ANTONY CHETTOOR MATHAI , CHANDRAN DIVYA , MADURAPPA ASHOK
发明人： PATELL VILLO MORAWALA , ANTONY CHETTOOR MATHAI , CHANDRAN DIVYA , MADURAPPA ASHOK
IPC分类号： C07K14/415 , C07K14/81 , C12N15/82
CPC分类号： C07K14/811 , C07K14/415 , C12N15/8273
摘要： The present invention relates to an isolated nucleic acid sequence AGT-SAL 11 encoding polypeptides which confers salt tolerance on plants and other organisms.
摘要翻译：本发明涉及编码赋予植物和其他生物体上的耐盐性的多肽的分离的核酸序列AGT-SAL11。

4. 发明申请

WO2007107853A3 PRODUCTION OF ALPHA-LINOLENIC ACID IN SUNFLOWER 审中-公开
标题翻译：在阳光下生产ALPHA-LINOLENIC酸
公开(公告)号：WO2007107853A3
公开(公告)日：2008-05-08
申请号：PCT/IB2007000694
申请日：2007-03-21
申请人： AVESTHA GENGRAINE TECH PVT LTD , PATELL VILLOO MORAWALA , RAJYASHRI K R
发明人： PATELL VILLOO MORAWALA , RAJYASHRI K R
IPC分类号： C12N15/82 , C07K14/415
CPC分类号： C12N15/8247 , C12N9/0071
摘要： The following invention relates to the method of transformation of Sunflower with Agrobacterium tumefaciens harboring the recombinant vector comprising the nucleic acid sequence encoding the enzyme, Delta- 15 desaturase required for alpha-linolenic acid biosynthesis, driven by ubiquitin promoter. Further disclosed are the nucleic acid sequences, constructs, vectors comprising the gene encoding for Delta- 15 desaturase enzyme required for the alpha-linolenic acid production in functional combination with the heterologous regulatory sequences and the host cells into which the vectors have been introduced. Further aspects of the invention relates to the selection and regeneration of the putative transformants based on a method of positive selection using Xylose as a selectable marker.
摘要翻译：以下发明涉及用含有编码由遍在蛋白启动子驱动的α-亚麻酸生物合成所需的Δ-15去饱和酶的核酸序列的重组载体的根癌土壤杆菌转化方法。进一步公开的核酸序列，构建体，包含编码与异源调节序列和载体已经被引入的宿主细胞的功能性组合中的α-亚麻酸产生所需的Δ-15去饱和酶的基因的载体。本发明的其它方面涉及基于使用木糖作为选择标记的阳性选择的方法来选择和再生推定的转化体。

5. 发明申请

WO2008007214A2 GLYCYRRHIZA GLABRA PLANT EXTRACTS FOR TREATING OSTEOPOROSIS AND THE EXTRACTION PROCESS THEREOF 审中-公开
标题翻译：用于治疗骨质疏松症的GLYCYRRHIZA GLABRA植物提取物及其提取方法
公开(公告)号：WO2008007214A2
公开(公告)日：2008-01-17
申请号：PCT/IB2007002054
申请日：2007-07-09
申请人： AVESTHA GENGRAINE TECH PVT LTD , PATELL VILLOO MORAWALA
发明人： PATELL VILLOO MORAWALA
CPC分类号： A61K36/484
摘要： The invention relates to compositions and methods for preventing, treating, or managing osteoporosis or conditions which are characterized by increased bone resorption, comprising administration of a prophylactically and therapeutically effective amount of Glycirrhiza glabra plant or extracts thereof to a mammal in need of such therapy. Preferably the mammal is human and the compositions comprise of single extract or a combination of extracts thereof. The present invention further relates to extracts which are isolated from different parts of Glycirrhiza glabra plant, the preparation of such extracts, the medicaments containing said extracts, and the use of these extracts and constituents for the preparation of a medicament. The present invention also relates to the process for preparing the extracts from various parts of Glycirrhiza glabra plant.
摘要翻译：本发明涉及用于预防，治疗或控制骨质疏松症或特征在于骨吸收增加的特征的组合物和方法，包括将预防和治疗有效量的甘草植物或其提取物施用于需要这种治疗的哺乳动物。优选地，哺乳动物是人，组合物包含单一提取物或其提取物的组合。本发明还涉及从甘草植物的不同部分分离的提取物，这些提取物的制备，含有所述提取物的药物，以及这些提取物和成分用于制备药物的用途。本发明还涉及从甘草植物的各个部分制备提取物的方法。

6. 发明申请

WO2006126066A3 A RECOMBINANT METHOD FOR PRODUCTION OF AN ERYTHROPOIESIS STIMULATING PROTEIN 审中-公开
标题翻译：一种用于生产红细胞生成素刺激蛋白的重组方法
公开(公告)号：WO2006126066A3
公开(公告)日：2007-07-12
申请号：PCT/IB2006001353
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD , MORAWALA PATELL VILLOO
发明人： MORAWALA PATELL VILLOO
IPC分类号： C07K14/505
CPC分类号： C07K14/505 , A61K38/00
摘要： The present invention relates to the recombinant method used for the production of a highly glycosylated form (in total five N linked glycosylations as opposed to three N linked glyosylations in the natural EPO) of erythropoietin. The added sites for glycosylation will result in greater number of carbohydrate chains, and higher sialic acid content than human EPO, which in turn would impart to the recombinant molecule a longer half-life. The invention further relates to the construction of expression cassettes comprising nucleic acid sequences encoding for the highly glycosylated form of Erythropoietin and stable expression in the host cells. The invention further relates to the optimized method for purification of the erythropoiesis stimulating protein. The recombinant EPO according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for an increase in the hematocrit for treatment of anemia and for restoration of patient well being and quality of life.
摘要翻译：本发明涉及用于生产高度糖基化形式（在天然EPO中与三个N连接的糖基化相反的总共5个N连接的糖基化）促红细胞生成素的重组方法。糖基化的添加位点将导致比人EPO更多的碳水化合物链和更高的唾液酸含量，其又赋予重组分子更长的半衰期。本发明还涉及包含编码高糖基化形式的红细胞生成素的核酸序列并在宿主细胞中稳定表达的表达盒的构建。本发明还涉及促红细胞生成蛋白的纯化的优化方法。根据本发明的重组EPO及其盐和功能衍生物可以包含药物组合物的活性成分，用于增加用于治疗贫血的血细胞比容和恢复患者的生活质量和生活质量。

7. 发明申请

WO2005016224A3 NOVEL THERAPEUTIC EXTRACTS AND MOLECULES FOR DEGENERATIVE CONDITIONS 审中-公开
标题翻译：新的治疗提取物和分解物的分解
公开(公告)号：WO2005016224A3
公开(公告)日：2006-03-16
申请号：PCT/IB2004002531
申请日：2004-07-23
申请人： AVESTHA GENGRAINE TECH PVT LTD , PATELL VILLOO MORAWALA
发明人： PATELL VILLOO MORAWALA
IPC分类号： A61K20060101 , A61K36/18 , A61K7/46
CPC分类号： A61K36/18
摘要： In this invention we have characterized plant extracts derived from common plants used in Indian traditional medicine using a) chemical fingerprinting by HPLC and b) etiology based in-vitro cell assays in order to reduce the extracts to minimum constituent to use for therapeutic purpose against degenerative conditions like cardiovascular diseases, Diabetes mellitus, Hypertension, All types of Cancers, Obesity & weight problems, Arthritis & pain, Alzheimer's disease, Multiple sclerosis & Autoimmune diseases, Asthma & Allergies, Osteoporosis & bone health, Parkinson's disease, Stress, Disorders & diseases of the eye. The current status of the extracts is that all of them have been chemically fingerprinted and have gone through assays to screen anti-diabetic activity. Thus currently we are applying for the specific leads that have shown very specific antidiabetic activity. However we are also working in parallel, to test these extracts in other assays, for generating information of there applicability in the prevention or treatment of degenerative conditions as mentioned above. As and when we will have data to support disease specific application of individual extracts we will amend our claims accordingly. The present invention relates to a composition for curing or treating degenerative disorders, a process for the preparation of the same, and usage of the same and, more particularly, to the composition having as a major component a single extract or multiple extracts containing therapeutically relevant bioactive, obtained from a certain kind of plant/plants and being capable of lowering or reducing a level of glucose in the blood of a patient suffering from diabetes mellitus by alleviating or ameliorating various symptoms caused by or associated with the diabetes mellitus as well as preventing the glucose level in the blood of the diabetic patient with high certainty from arising again. The invention also relates to the in-vitro screening of plant extracts for anti-diabetic activities in multiple cell based and biochemical systems. Studies have shown eleven potential leads, which are very valuable as they could lead to bioactives having therapeutic activity in the treatment of like cardiovascular diseases, Diabetes mellitus, Hypertension, All types of Cancers, Obesity & weight problems, arthritis and pain, Alzheimer's disease, multiple sclerosis and autoimmune diseases, asthma and allergies, osteoporosis and bone health, Parkinson's disease, stress, disorders and diseases of the eye.
摘要翻译：在本发明中，我们已经表征了从印度传统医学中使用的普通植物得到的植物提取物，其使用以下方法：a）通过HPLC进行化学指纹图谱，以及b）基于病毒学的体外细胞测定法，以将提取物减少至用于治疗目的的最小成分疾病如心血管疾病，糖尿病，高血压，所有类型的癌症，肥胖和体重问题，关节炎和疼痛，阿尔茨海默病，多发性硬化症和自身免疫疾病，哮喘和过敏，骨质疏松症和骨骼健康，帕金森病，压力，疾病和疾病的眼睛。提取物的当前状态是所有这些都是化学指纹图谱，并且已经通过测定来筛选抗糖尿病活性。因此，目前我们正在申请已显示非常具体的抗糖尿病活动的具体潜在客户。然而，我们也正在并行工作，以测试其他测定中的这些提取物，以产生在预防或治疗如上所述的退行性疾病中的适用性的信息。当我们将有数据支持个别提取物的疾病具体应用时，我们将相应地修改我们的声明。本发明涉及一种用于治疗或治疗退行性疾病的组合物，其制备方法及其用途，更具体地说，涉及作为主要成分的组合物的单一提取物或含有治疗相关性的多种提取物从某种植物获得的生物活性物质，并且通过减轻或改善由糖尿病引起的或与糖尿病有关的各种症状，并且能够降低或降低患有糖尿病的患者的血液中的葡萄糖水平，以及预防糖尿病患者血液中的葡萄糖水平高可靠性再次出现。本发明还涉及用于多细胞和生物化学系统中抗糖尿病活性的植物提取物的体外筛选。研究显示十一个潜在的引线，这是非常有价值的，因为它们可能导致在治疗类似的心血管疾病，糖尿病，高血压，所有类型的癌症，肥胖和体重问题，关节炎和疼痛，阿尔茨海默病，多发性硬化症和自身免疫疾病，哮喘和过敏，骨质疏松症和骨骼健康，帕金森氏病，压力，疾病和眼疾。

8. 发明申请

WO2008007215A2 BERBERIS ARISTATA PLANTS EXTRACTS FOR TREATING OSTEOPOROSIS AND THE EXTRACTION PROCESS THEREOF 审中-公开
标题翻译： BERBERIS ARISTATA植物提取物治疗骨质疏松症及其提取过程
公开(公告)号：WO2008007215A2
公开(公告)日：2008-01-17
申请号：PCT/IB2007002091
申请日：2007-07-09
申请人： AVESTHA GENGRAINE TECH PVT LTD , PATTELL VILLOO MORAWALA
发明人： PATTELL VILLOO MORAWALA
CPC分类号： A61K36/29
摘要： The invention relates to compositions and methods for preventing, treating, or managing osteoporosis or conditions which are characterized by increased bone resorption, comprising administration of a prophylactically and therapeutically effective amount of Berberis aristata plant or extracts thereof to a mammal in need of such therapy. Preferably the mammal is human and the compositions comprise of single extract or a combination of extracts thereof. The present invention further relates to extracts which are isolated from different parts of Berberis aristata plant, the preparation of such extracts, the medicaments containing said extracts, and the use of these extracts and constituents for the preparation of a medicament. The present invention also relates to the process for preparing the extracts from various parts of Berberis aristata plant.
摘要翻译：本发明涉及用于预防，治疗或控制骨质疏松症或其特征在于增加的骨吸收的病症的组合物和方法，包括向需要这种治疗的哺乳动物施用预防和治疗有效量的小檗属植物或其提取物。优选地，哺乳动物是人，组合物包含单一提取物或其提取物的组合。本发明还涉及从小檗属植物的不同部分分离的提取物，这些提取物的制备，含有所述提取物的药物，以及这些提取物和成分用于制备药物的用途。本发明还涉及从小檗植物的各个部分制备提取物的方法。

9. 发明申请

WO2006126068A3 RECOMBINANT METHOD FOR THE PRODUCTION OF A MONOCLONAL ANTIBODY TO CD52 FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA 审中-公开
标题翻译：用于生产单克隆抗体至CD52用于治疗慢性淋巴细胞白血病的重组方法
公开(公告)号：WO2006126068A3
公开(公告)日：2007-08-23
申请号：PCT/IB2006001356
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD , PATELL VILLOO MORAWALA
发明人： PATELL VILLOO MORAWALA
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2893 , C07K2317/24
摘要： The present invention relates to the recombinant method used for the production of soluble form monoclonal antibody that binds to CD52. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD 52, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.
摘要翻译：本发明涉及用于生产结合CD52的可溶形式单克隆抗体的重组方法。该方法描述了编码抗-CD52的核酸序列的从头合成，将构建的核酸序列转化为感受态细菌，并将其亚克隆至用于表达所需蛋白质的哺乳动物表达载体中。已经公开了包含与感兴趣的基因相关的对照元件的DNA构建体。感兴趣的核酸序列已被密码子优化以允许在合适的哺乳动物宿主细胞中表达。

10. 发明申请

WO2006126070A3 A PROCESS COMPRISING CODON OPTIMIZATION FOR THE PRODUCTION OF RECOMBINANT ACTIVATED HUMAN PROTEIN C FOR THE TREATMENT OF SEPSIS 审中-公开
标题翻译：包含用于生产重组激活的人类蛋白C用于治疗食欲的代码优化的方法
公开(公告)号：WO2006126070A3
公开(公告)日：2007-04-12
申请号：PCT/IB2006001359
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD , PATELL VILLOO MORAWALA
发明人： PATELL VILLOO MORAWALA
IPC分类号： C12N9/64 , C12N15/85
CPC分类号： C12N15/85 , C12N9/6464 , C12N2840/203 , C12Y304/21069
摘要： The present invention relates to a recombinant method of production of activated Protein C. The invention relates to a method of construction, transformation, expression, purification and production of recombinant activated human protein C. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.
摘要翻译：本发明涉及生物活化蛋白C的重组方法。本发明涉及重组活化的人蛋白质C的构建，转化，表达，纯化和生产的方法。包含与感兴趣的基因相关的对照元件的DNA构建体已被披露。感兴趣的核酸序列已被密码子优化以允许在合适的哺乳动物宿主细胞中表达。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式